Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Crowther

Showing results (51-60 of 286) with videos related to

Pageof 29
Sort By:
Clinical Advances in Hematology & Oncology : H&O|September 21, 2005
New anticoagulants: an updateMark Crowther, Jeffrey I Weitz
Journal of Thrombosis and Thrombolysis|February 27, 2013
Proceedings of the 12th National Conference on Anticoagulant TherapyDavid A Garcia, Mark Crowther
Thrombosis Research|October 3, 2002
Direct thrombin inhibitorsJeffrey I Weitz, Mark Crowther
Current Rheumatology Reports|April 29, 2010
Intensity of warfarin coagulation in the antiphospholipid syndromeMark Crowther, Mark A Crowther
European Journal of Internal Medicine|July 27, 2019
North America anticoagulation forum guidance on reversal of direct oral anticoagulantsWilliam Gansheng Shi, Mark Crowther
Arteriosclerosis, Thrombosis, and Vascular Biology|June 20, 2015
Antidotes for novel oral anticoagulants: current status and future potentialMark Crowther, Mark A Crowther
Hematology/Oncology Clinics of North America|July 28, 2010
Hematology/Oncology Clinics of North America. Hypercoagulable states and new anticoagulants. PrefaceMark Crowther, Marco P Donadini
Hematology/Oncology Clinics of North America|July 28, 2010
Antiphospholipid syndrome: a challenging hypercoagulable state with systemic manifestationsMarco P Donadini, Mark Crowther
Evidence-Based Medicine|March 16, 2012
Thromboprophylaxis in medical inpatients reduces pulmonary embolism, increases the risk of major haemorrhage and does not reduce total mortality, producing questionable net clinical benefitMark Crowther, David G Gracia
Methods in Molecular Biology (Clifton, N.J.)|April 3, 2013
Lupus anticoagulant testingKaren Moffat, Anne Raby, Mark Crowther
Pageof 29

Showing results (51-60 of 286) with videos related to

Sort By:
Pageof 29
Clinical Advances in Hematology & Oncology : H&O|September 21, 2005
New anticoagulants: an updateMark Crowther, Jeffrey I Weitz
Journal of Thrombosis and Thrombolysis|February 27, 2013
Proceedings of the 12th National Conference on Anticoagulant TherapyDavid A Garcia, Mark Crowther
Thrombosis Research|October 3, 2002
Direct thrombin inhibitorsJeffrey I Weitz, Mark Crowther
Current Rheumatology Reports|April 29, 2010
Intensity of warfarin coagulation in the antiphospholipid syndromeMark Crowther, Mark A Crowther
European Journal of Internal Medicine|July 27, 2019
North America anticoagulation forum guidance on reversal of direct oral anticoagulantsWilliam Gansheng Shi, Mark Crowther
Arteriosclerosis, Thrombosis, and Vascular Biology|June 20, 2015
Antidotes for novel oral anticoagulants: current status and future potentialMark Crowther, Mark A Crowther
Hematology/Oncology Clinics of North America|July 28, 2010
Hematology/Oncology Clinics of North America. Hypercoagulable states and new anticoagulants. PrefaceMark Crowther, Marco P Donadini
Hematology/Oncology Clinics of North America|July 28, 2010
Antiphospholipid syndrome: a challenging hypercoagulable state with systemic manifestationsMarco P Donadini, Mark Crowther
Evidence-Based Medicine|March 16, 2012
Thromboprophylaxis in medical inpatients reduces pulmonary embolism, increases the risk of major haemorrhage and does not reduce total mortality, producing questionable net clinical benefitMark Crowther, David G Gracia
Methods in Molecular Biology (Clifton, N.J.)|April 3, 2013
Lupus anticoagulant testingKaren Moffat, Anne Raby, Mark Crowther
Pageof 29